Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.3M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
27.5M
-
Shares change
-
+984K
-
Total reported value, excl. options
-
$541M
-
Value change
-
+$19.1M
-
Number of buys
-
23
-
Number of sells
-
-14
-
Price
-
$19.73
Significant Holders of Janux Therapeutics, Inc. - Common Stock (JANX) as of Q4 2021
50 filings reported holding JANX - Janux Therapeutics, Inc. - Common Stock as of Q4 2021.
Janux Therapeutics, Inc. - Common Stock (JANX) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.5M shares
of 60.3M outstanding shares and own 45.56% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.67M shares), FMR LLC (4.99M shares), ORBIMED ADVISORS LLC (2.84M shares), JANUS HENDERSON GROUP PLC (2.4M shares), CITADEL ADVISORS LLC (1.85M shares), EcoR1 Capital, LLC (1.41M shares), BVF INC/IL (1.02M shares), BlackRock Inc. (1.01M shares), VANGUARD GROUP INC (533K shares), and 5AM Venture Management, LLC (446K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.